With Newly Raised Funds, Exact Sciences Readying Cologuard for Commercialization | GenomeWeb

Originally published June 24.

Following the submission of its last data module for the Cologuard test with the US Food and Drug Administration, Exact Sciences announced this week that it had raised more than $73 million in net proceeds from a public offering of its common stock.

Exact Sciences said in a statement that the funds give the company working capital that might go toward product development and commercialization activities, and be used to garner FDA approval for Cologuard.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.